Gharagozlou Parham, Demirci Hasan, David Clark J, Lameh Jelveh
Department of Pharmacology, Molecular Research Institute, Mountain View, CA 94043, U.S.A.
Department of Anaesthesiology, VA Palo Alto Health Care System, Palo Alto, CA, 94034, U.S.A.
BMC Pharmacol. 2003 Jan 4;3:1. doi: 10.1186/1471-2210-3-1.
The aim of the present study was to describe the activity of a set of opioid drugs, including partial agonists, in a cell system expressing only mu opioid receptors. Receptor activation was assessed by measuring the inhibition of forskolin-stimulated cyclic adenosine mono phosphate (cAMP) production. Efficacies and potencies of these ligands were determined relative to the endogenous ligand beta-endorphin and the common mu agonist, morphine.
Among the ligands studied naltrexone, WIN 44,441 and SKF 10047, were classified as antagonists, while the remaining ligands were agonists. Agonist efficacy was assessed by determining the extent of inhibition of forskolin-stimulated cAMP production. The rank order of efficacy of the agonists was fentanyl = hydromorphone = beta-endorphin > etorphine = lofentanil = butorphanol = morphine = nalbuphine = nalorphine > cyclazocine = dezocine = metazocine >or= xorphanol. The rank order of potency of these ligands was different from that of their efficacies; etorphine > hydromorphone > dezocine > xorphanol = nalorphine = butorphanol = lofentanil > metazocine > nalbuphine > cyclazocine > fentanyl > morphine >>>> beta-endorphin.
These results elucidate the relative activities of a set of opioid ligands at mu opioid receptor and can serve as the initial step in a systematic study leading to understanding of the mode of action of opioid ligands at this receptor. Furthermore, these results can assist in understanding the physiological effect of many opioid ligands acting through mu opioid receptors.
本研究的目的是描述一组阿片类药物(包括部分激动剂)在仅表达μ阿片受体的细胞系统中的活性。通过测量对福司可林刺激的环磷酸腺苷(cAMP)产生的抑制作用来评估受体激活情况。相对于内源性配体β-内啡肽和常见的μ激动剂吗啡,确定了这些配体的效能和效价。
在所研究的配体中,纳曲酮、WIN 44,441和SKF 10047被归类为拮抗剂,而其余配体为激动剂。通过确定对福司可林刺激的cAMP产生的抑制程度来评估激动剂的效能。激动剂效能的排序为芬太尼 = 氢吗啡酮 = β-内啡肽 > 埃托啡 = 洛芬太尼 = 布托啡诺 = 吗啡 = 纳布啡 = 纳洛芬 > 环唑辛 = 地佐辛 = 美他佐辛 ≥ 羟吗啡醇。这些配体的效价排序与其效能排序不同;埃托啡 > 氢吗啡酮 > 地佐辛 > 羟吗啡醇 = 纳洛芬 = 布托啡诺 = 洛芬太尼 > 美他佐辛 > 纳布啡 > 环唑辛 > 芬太尼 > 吗啡 >>>> β-内啡肽。
这些结果阐明了一组阿片类配体在μ阿片受体上的相对活性,可作为系统研究的第一步,以了解阿片类配体在该受体上的作用模式。此外,这些结果有助于理解许多通过μ阿片受体起作用的阿片类配体的生理效应。